Instituto Portugues de Reumatologia | Lisbon, Portugal

Research site

(Unclaimed)

Location

7 Rua da Benificiencia, Lisbon, Lisbon, Portugal

Site insights

Top conditions

Top treatments

Upadacitinib

ABT-494

Methotrexate

Adalimumab

MTX

Cenerimod

BMS-986165

Baricitinib

Deucravacitinib

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 12 total trials

Locations recently updated

A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus (OPUS-2)

The goal of this clinical trial is to see how well cenerimod reduces symptoms of Systemic Lupus Erythematous in adult patients with moderate to sever...

Enrolling

Lupus Erythematosus, Systemic

Drug: Cenerimod

Drug: Placebo

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate (SELECT-COMPARE)

The purpose of this study was to assess efficacy, including inhibition of radiographic progression, and safety with upadacitinib versus placebo and v...

Active, not recruiting

Rheumatoid Arthritis

Drug: Placebo for Upadacitinib

Drug: Upadacitinib

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) (SELECT - PsA 1)

This study includes two periods. The main objective of Period 1 is to compare the efficacy of upadacitinib 15 mg once daily (QD) and 30 mg QD versus...

Active, not recruiting

Psoriatic Arthritis

Drug: Adalimumab

Drug: Placebo to Adalimumab

A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) (SELECT - PsA 2)

The study objectives of Period 1 are to compare the efficacy, safety, and tolerability of upadacitinib 15 mg once daily (QD) and 30 mg QD versus plac...

Active, not recruiting

Psoriatic Arthritis

Drug: Placebo

Drug: Upadacitinib

A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (POETYK SLE-2)

The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe System...

Enrolling

Systemic Lupus Erythematosus

Drug: Deucravacitinib

Other: Placebo

Trial sponsors

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms